Recro Pharma (REPH) News Today → Elon Musk’s PRIME is Set to Shock the World (From InvestorPlace) (Ad) Free REPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative January 30, 2024 | wsj.comFuji Pharma Co. Ltd.November 7, 2023 | markets.businessinsider.comHere's what Wall Street expects from Recro Pharma's earnings reportAugust 16, 2023 | theguardian.comUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitsAugust 9, 2023 | markets.businessinsider.comWhat Wall Street expects from Recro Pharma's earningsAugust 3, 2023 | investing.comMankind Pharma Ltd (MNKI)June 30, 2023 | bizjournals.comBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsJune 24, 2022 | benzinga.comPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLApril 20, 2022 | reuters.comSocietal CDMO IncMarch 22, 2022 | finanznachrichten.deRecro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and TransformationMarch 22, 2022 | finance.yahoo.comIs Recro Pharma (REPH) a Worthy Investment?March 18, 2022 | marketbeat.comRecro Pharma (NASDAQ:REPH) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on shares of Recro Pharma in a research report on Friday. They set a "hold" rating on the stock.March 2, 2022 | marketbeat.comRecro Pharma (NASDAQ:REPH) Coverage Initiated by Analysts at StockNews.comStockNews.com assumed coverage on shares of Recro Pharma in a research report on Wednesday. They set a "hold" rating for the company.March 1, 2022 | benzinga.comRecap: Recro Pharma Q4 EarningsFebruary 23, 2022 | finance.yahoo.comRecro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego FacilityFebruary 22, 2022 | finance.yahoo.comRecro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022January 26, 2022 | finance.yahoo.comRecro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer PreventionJanuary 6, 2022 | marketbeat.comRecro Pharma (NASDAQ:REPH) Downgraded by Zacks Investment ResearchZacks Investment Research cut shares of Recro Pharma from a "hold" rating to a "sell" rating in a research report on Thursday.January 3, 2022 | finance.yahoo.comRecro to Present at H.C. Wainwright BioConnect 2022 ConferenceDecember 8, 2021 | finance.yahoo.comDo Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?December 8, 2021 | marketbeat.comRecro Pharma (NASDAQ:REPH) Cut to "Hold" at Zacks Investment ResearchZacks Investment Research cut shares of Recro Pharma from a "buy" rating to a "hold" rating in a research note on Wednesday.November 2, 2021 | finance.yahoo.comRecro to Report Financial Results for Third Quarter 2021 on November 9, 2021October 27, 2021 | finance.yahoo.comRecro Enters Into Master Commercial Supply and Services Agreement With OtsukaSeptember 21, 2021 | marketwatch.comRecro Pharma Signs Renewable Energy Agreement with Georgia PowerSeptember 21, 2021 | finance.yahoo.comRecro Signs Renewable Energy Agreement With Georgia PowerSeptember 16, 2021 | finance.yahoo.comRecro Pharma (REPH) Moves to Buy: Rationale Behind the UpgradeAugust 16, 2021 | bizjournals.comRecro Pharma goes bicoastal with 'transformative' acquisition of San Diego firm for $50MAugust 13, 2021 | marketwatch.comRecro Pharma Buys San Diego-Based Irisys for $50 Million >REPHAugust 13, 2021 | finance.yahoo.comRecro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMOAugust 10, 2021 | finance.yahoo.comRecro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMOAugust 7, 2021 | markets.businessinsider.comRecro Pharma is about to announce its earnings — here's what to expectAugust 6, 2021 | markets.businessinsider.comRecro Pharma Inc hosts conference call for investorsAugust 2, 2021 | finance.yahoo.comRecro To Report Financial Results for Second Quarter 2021 on August 9, 2021 Get Recro Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 investment for 2024 (Ad)It’s something you use every single day and don’t even know it. Click here to see my #1 investment for 2024. REPH Media Mentions By Week REPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPH News Sentiment▼0.000.50▲Average Medical News Sentiment REPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPH Articles This Week▼00▲REPH Articles Average Week Get Recro Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cellectar Biosciences News OptiNose News Societal CDMO News Rezolute News Relmada Therapeutics News Coya Therapeutics News PMV Pharmaceuticals News Cartesian Therapeutics News Immunic News Abeona Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REPH) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressProtect Your Bank Account Before It’s Too LateWeiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recro Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
